Progress in Obesity Solutions: Health Care Systems

FATIMA CODY STANFORD, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS

OBESITY MEDICINE & NUTRITION

AMERICAN BOARD OF OBESITY MEDICINE DIPLOMATE







Disclosures

- Advisor/ Consultant- Novo Nordisk, Currax, Boehringer Ingelheim, Eli Lilly, Pfizer, Calibrate, Coral Health, Gelesis, GoodRx, Sweetch, Life Force, Veri
- ► Research- Amazon





Objectives

Discern

 Discern the complexity of obesity as a chronic disease

Learn

 Learn about the problem of BMI as a metric

Determine

 Determine the deleterious impact of weight bias on health outcomes

Ascertain

 Ascertain treatment strategies regarding obesity and issues within health systems

Obesity: A Multi-factorial Disorder



Genetics



Environment




Development



Behavior
















Maternal/ Developmental Economic

Food and Beverage

Psychological




Regulation of Food Intake







Regulation of Food Intake








Adolphe Quetelet











Eugenics



The study of how to arrange reproduction within a human population to increase the occurrence of heritable characteristics regarded as desirable. Developed largely by Sir Francis Galton as a method of improving the human race, eugenics was increasingly discredited as unscientific and racially biased during the 20th century, especially after the adoption of its doctrines by the Nazis in order to justify their treatment of Jews, disabled people, and other minority groups.









How is Obesity defined in Adults?

Weight Status Category	Body Mass Index (BMI)
Underweight	< 18.5
Normal Weight	18.5-24.9
Overweight	25- 29.9
Class I Obesity	30-34.9
Class II Obesity	35-39.9
Class III Obesity	≥40






Adjustment of BMI Scale for Race, Gender, and Obesity Related Diseases

	BMI (kg/m ²)						
	Men			Women			
Obesity Co-morbidity	Black	Hispanic	White	Black	Hispanic	White	
Hypertension	28	29	28	31	28	27	
Dyslipidemia	27	26	27	29	27	25	
Diabetes	29	29	30	33	30	29	
≥2 risk factors	28	29	29	31	30	28	
Average	28	28	29	31	29	27	






Age-adjusted prevalence of obesity among adults aged 20 and over, by sex and race and Hispanic origin: United States, 2017–2018








Age-adjusted prevalence of severe obesity among adults aged 20 and over, by sex, age, and race and Hispanic origin: United States, 2017–2018















Overcoming Weight Stigma in the Treatment of Obesity









Mayo Clin Proc. 2021 Dec;96(12):2991-3000.. doi: 10.1016/j.mayocp.2021.07.021



TABLE 4. Logistic Regression Results for Predicting the Odds of an Antiobesity Drug Mention for the Overall Population of Patients With Obesity From 2011 to 2016.

	Adjusted odds	
Predictor	ratio	95% CI
Sex, female	2.30	0.61-8.63
Race, White	1.04	0.36-2.97
Patient age, ≥51 years	0.14	0.02-0.82
Provider region Northeast South Midwest or West	1.19 3.69 1.00	0.23-6.12 1.17-11.63
Insurance type Private Public or other ^a Self-pay	1.00 0.16 0.72	0.24-6.66 0.12-4.23
Patient's primary care physician	3.54	0.96-13.07
Total comorbidities ≤I comorbidity ≥I comorbidity	0.14 1.00 2.04	0.02-0.82
^a Other includes workers'	compensation	no charge and

^aOther includes workers' compensation, no charge, and charity.


Estimate of Bariatric Surgery Numbers, 2011-2019

	2011	2012	2013	2014	2015	2016	2017	2018	2019*
Total	158,000	173,000	179,000	193,000	196,000	216,000	228,000	252,000	256,000
Sleeve	17.8%	33.0%	42.1%	51.7%	53.6%	58.1%	59.4%	61.4%	59.4%
RYGB	36.7%	37.5%	34.2%	26.8%	23.0%	18.7%	17.8%	17.0%	17.8%
Band	35.4%	20.2%	14.0%	9.5%	5.7%	3.4%	2.7%	1.1%	0.9%
BPD-DS	0.9%	1.0%	1.0%	0.4%	0.6%	0.6%	0.7%	0.8%	0.9%
Revision	6.0%	6.0%	6.0%	11.5%	13.6%	14.0%	14.1%	15.4%	16.7%
Other	3.2%	2.3%	2.7%	0.1%	3.2%	2.6%	2.5%	2.3%	2.4%
Balloons	_	-	-	-	0.3%	2.6%	2.8%	2.0%	1.8%

The ASMBS total bariatric procedure numbers are based on the best estimation from available data (BOLD, ACS/MBSAQIP, National Inpatient Sample Data and outpatient estimates

*New methodology for estimating outpatient procedures done at non-accredited centers.

Economic impacts of overweight and obesity, 2019 and 2060, by country. *Upper middle-income. **Lower middle-income. ***Low-income.











Obesity Impact on Global GDP










Where Obesity Places The Biggest Burden On Healthcare

Average annual health expenditure per capita due to obesity from 2020-2050*





 $[\]ensuremath{^*}$ U.S. dollars - purchasing power parity.

@StatistaCharts Source: OECD



Obesity Policies and Targets

	Adult obesity (%)	Adult overweight (%)	Combined adulto/w and obese (%)	National obesity targets?*	National obesity policy?	State-level obesity policy?	Guidance on surgery/drugs?
Brazil	17.4	33.6	51.0	√√	√√	n/a	✓
Bulgaria	23.7	34.5	58.2	√√	✓	n/a	X
Canada	18.4	34.1	52.5	√√	√√	✓	√√
Denmark	14.1	33.3	47.4	✓	✓	n/a	√√
England	24.8	37.1	61.9	√√	√√	n/a	√√
France	15.0	32.6	47.6	√√	√√	n/a	√√
Germany	23.6	36.5	60.1	√√	√√	✓	√√
Italy	10.3	36.5	46.8	✓	✓	n/a	√√
Mexico	32.2	39.1	71.3	✓	✓	n/a	√√
Spain	22.9	39.4	62.3	X	√√	n/a	√√
United States	35.7	33.1	68.8	√√	Х	✓	√√





Summary

- Obesity is a multifactorial disorder
- ▶ BMI is a problematic metric for ascertaining weight status
- Weight stigma has a negative impact on the health and psychological health of patients who struggle with obesity
- Pharmacotherapy and/or bariatric surgery should be considered as an option for appropriate patients
- The economic impacts of obesity is vast-policy is lacking in the US





Thank You For Your Time

Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS fstanford@mgh.harvard.edu









